The expression and modulation of CEACAM1 and tumor cell transformation

Annali dell'Istituto Superiore di Sanita

Volumn 48, Issue 2, 2012, Pages 161-171

  Fiori, Valentina ^a   Magnani, Mauro ^b   Cianfriglia, Maurizio ^c  

^a Diatheva srl ^*  (Italy)

^b UNIVERSITY OF URBINO   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Cancer; CEACAM1; Dysregulation; Melanoma; NSCLC; Poor prognosis

Indexed keywords

CD66 ANTIGENS; CELL ADHESION MOLECULE; ID1 PROTEIN, HUMAN; INHIBITOR OF DIFFERENTIATION 1; ISOPROTEIN; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; TUMOR ANTIGEN; TUMOR MARKER; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

BIOSYNTHESIS; CARCINOMA; CELL TRANSFORMATION; COLON TUMOR; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MELANOMA; METABOLISM; METASTASIS; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; REVIEW; TRANSPLANTATION; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, NEOPLASM; CARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; COLONIC NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF DIFFERENTIATION PROTEIN 1; LUNG NEOPLASMS; MELANOMA; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PROGNOSIS; PROTEIN ISOFORMS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84863310076     PISSN: 00212571     EISSN: None     Source Type: Journal    
DOI: 10.4415/ANN_12_02_09     Document Type: Review

References (74)

1. Hammarstrom S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 1999;9:67-81. http://dx.doi.org/10.1006/scbi.1998.0119 (Pubitemid 29265523)
2. De Angelis M, Heinrich G, Dai T, Bowman TA, Patel PR, Lee SJ, Hong EG, Jung DY, Assmann A, Kulkarni, RN, Kim JK e Najjar S. Carcinoembryonic antigen-related cell adhesion molecule I. A link between insulin and lipid metabolism. Diabetes 2008;57:2296-303. http://dx.doi.org/10.2337/db08-0379
3. Wagener C, Ergün S. Angiogenic properties of the carcinoembryonic antigen-related cell adhesion molecule 1. Exp Cell Res 2000;261(1):19-24. http://dx.doi.org/10.1006/excr.2000.5038
4. Gray-Owen SD, Blumberg RS. CEACAM1: contact-dependent control of immunity. Nat Rev Immunol 2006;6(6):433-46. http://dx.doi.org/10.1038/nril864
5. Gray-Owen SD. Neisserial Opa proteins: impact on colonization, dissemination and immunity. Scand J Infect Dis 2003;35(9):614-8. http://dx.doi.org/10.1080/00365540310016042 (Pubitemid 37336882)
6. Hemmila E, Turbide C, Olson M, Jothy S, Holmes KV, Beauchemin N. Ceacamla-/-mice are completely resistant to infection by murine coronavirus mouse hepatitis virus A59. J Virol 2004;78(18):10156-65. http://dx.doi.org/10. 1128/JVI.78.18.10156-10165.2004 (Pubitemid 39187133)
7. Voges M, Bachmann V, Kammerer R, Gophna U, Hauck CR. CEACAM1 recognition by bacterial pathogens is species-specific. BMC Microbiol 2010;10:117-28. http://dx.doi.org/10.1186/1471-2180-10-117
8. Kuespert K, Pils S, Hauck CR. CEACAMs: their role in physiology and pathophysiology. Curr Opin Cell Biol 2006;18:565-71. http://dx.doi.org/10.1016/ j.ceb.2006.08.008 (Pubitemid 44332912)
9. Watt SM, Teixeira AM, Zhou GQ, Doyonnas R, Zhang Y, Grunert F, Blumberg RS, Kuroki M, Skubitz KM, Bates PA. Homophilic adhesion of human CEACAM1 involves N-terminal domain interactions: structural analysis of the binding site. Blood 2001;98:1469-79. http://dx.doi.org/10.1182/blood. V98.5.1469
10. Stern N, Markel G, Arnon TI, Gruda R, Wong H, Gray-Owen SD, Mandelboim O. Carcinoembryonic antigen (CEA) inhibits NK killing via interaction with CEA-related cell adhesion molecule 1. J Immunol 2005;174:6692-701. (Pubitemid 40705631)
11. Chen T, Zimmermann W, Parker J, Chen I, Maeda A, Bolland S. Biliary glycoprotein (BGPa, CD66a, CEACAM1) mediates inhibitory signals. J Leukocyte Biol 2001;70:335-40. (Pubitemid 32751527)
12. Kammerer R, Riesenberg R, Weiler C, Lohrmann J, Schleypen J, Zimmermann W. The tumor suppressor gene CEACAM1 is completely but reversibly downregulated in renal cell carcinoma. J Pathol 2004;204(3):258-67. http://dx.doi.org/10.1002/ path.1657 (Pubitemid 39430084)
13. Thies A, Moll I, Berger J, Wagener C, Brummer J, Schulze HJ, Brunner G, Schumacher U. CEACAM-1 expression in cutaneous malignant melanoma predicts the development of metastatic disease. J Clin Oncol 2002;20:2530-6. http://dx.doi.org/10.1200/JCO.2002.05.033 (Pubitemid 34525740)
14. Laack E, Nikbakht H, Peters A, Kugler C, Jasiewicz Y, Edler L, Brummer J, Schumacher U, Hossfeld DK. Expression of CEACAM-1 in adenocarcinoma of the lung: a factor of independent prognostic significance. J Clin Oncol 2002;20:4279-84. http://dx.doi.org/10.1200/JCO.2002.08.067 (Pubitemid 35266287)
15. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat Biotechnol 2005;23(9):1073-8. http://dx.doi.org/10. 1038/nbt0905-1073 (Pubitemid 41486385)
16. Carter P. Improving the efficacy of antibody-based cancer therapies. Nature Rev Cancer 2001;118:29. http://dx.doi.org/10.1038/35101072
17. Payne G. Progress in immunoconjugate cancer therapeutics. Cancer Cell 2003;3:207-12. http://dx.doi.org/10.1016/S1535-6108 (03) 00057-6 (Pubitemid 37443876)
18. Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. Nature Rev Drug Discov 2006;5:147-59. http://dx.doi.org/10.1038/ nrdl957
19. Senter PD. Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol 2009;13:235-44. http://dx.doi.org/10.1016/j.cbpa.2009.03.023
20. Neumaier M, Paululat S, Chan A, Matthaes P, Wagener C. Biliary glycoprotein, a potential human cell adhesion molecule, is down-regulated in colorectal carcinomas. Proc Natl Acad Sci USA 1993;90:10744-8. http://dx.doi.org/10.1073/pnas.90.22.10744 (Pubitemid 23347119)
21. Bamberger AM, Riethdorf L, Nollau P, Naumann M, Erdmann I, Gotze J, Brummer J, Schulte H M, Wagener C, Loning T. Dysregulated expression of CD66a (BGP C-CAM), an adhesion molecule of the CEA family, in endometrial cancer. Am J Pathol 1998;152:1401-6. (Pubitemid 28274997)
22. Riethdorf L, Liboa BW, Henkel U, Naumann M, Wagener C, Löning T. Differential expression of CD66a (BGP), a cell adhesion molecule of the carcinoembryonic antigen family, in benign, premalignant, and malignant lesions of the human mammary gland. J Histochem Cytochem 1997;45:957-63. http://dx.doi.org/10.1177/002215549704500705 (Pubitemid 27284019)
23. Lin SH, Pu YS. Function and therapeutic implication of C-CAM cell-adhesion molecule in prostate cancer. Semin Oncol 1999;26(2):227-33.
24. Luo W, Tapolsky M, Earley K, Wood CG, Wilson DR, Logothetis CJ, Lin SH. Tumor-suppressive activity of CD66a in prostate cancer. Cancer Gene Ther 1999;6:313-21. (Pubitemid 129667803)
25. Thies A, Berlin A, Brunner G, Schulze HJ, Moll I, Pfüller U, Wagener C, Schachner M, Altevogt P, Schumacher U. Glycoconjugate profiling of primary melanoma and its sentinel node and distant metastases: implications for diagnosis and pathophysiology of metastases. Cancer Lett 2007;248(1):68-80. http://dx.doi.org/10.1016/j.canlet.2006.05.020 (Pubitemid 46335725)
26. Thies A, Pfüller U, Schachner M, Horny HP, Moll I, Schumacher U. Binding of mistletoe lectins to cutaneous malignant melanoma: Implications for prognosis and therapy. Anticancer Res 2001;21:2883-7. (Pubitemid 33051146)
27. Thies A, Moll I, Berger J, Schumacher U. Lectin binding to cutaneous malignant melanoma: HPA is associated with metastasis formation. Br J Cancer 2001;84:819-23. http://dx.doi.org/10.1054/bjoc.2000.1673 (Pubitemid 32275657)
28. Gambichler T, Grothe S, Rotterdam S, Altmeyer P, Kreuter A. Protein expression of carcinoembryonic antigen cell adhesion molecules in benign and malignant melanocytic skin lesions. Am J Clin Pathol 2009;131(6):782-87. http://dx.doi.org/10.1309/AJCP24KXJVBZXENS
29. Markel G, Seidman R, Cohen Y, Besser MJ, Sinai TC, Treves AJ, Orenstein A, Berger R, Schachter J. Dynamic expression of protective CEACAM 1 on melanoma cells during specific immune attack. Immunology 2009;126(2):186-200. http://dx.doi.org/10.1111/j.1365-2567.2008.02888.x
30. Markel G, Lieberman N, Katz G, Anion TI, Lotem M, Drize O, Blumberg RS, Bar-Haim E, Mader R, Eisenbach L, Mandelboim O. CD66 interactions between human melanoma and NK cells: a novel class I MHC-independent inhibitory mechanism of cytotoxicity. J Immunol 2002;168:2803-10. (Pubitemid 34211659)
31. Markel G, Wolf D, Hanna J, Gazit R, Goldman-Wohl D, Lavy Y, Yagel S, Mandelboim O. Pivotal role of CEAC AM1 protein in the inhibition of activated decidual lymphocyte functions. J Clin Invest 2002;110:943-53. http://dx.doi.org/10.1172/JCI200215643
32. Markel G, Seidman R, Stern N, Cohen-Sinai T, Izhaki O, Katz G, Besser M, Treves AJ, Blumberg RS, Loewenthal R, Mandelboim O, Orenstein A, Schachter J. Inhibition of human tumor-in Wltrating lymphocyte eVector functions by the hemophilic carcinoembryonic cell adhesion molecule 1 interactions. J Immunol 2006;177:6062-71. (Pubitemid 44628821)
33. Sanders DS, Evans AT, Allen CA, Bryant FJ, Johnson GD, Hopkins J, Stocks SC, Marsden JR, Kerr MA. Classification of CEA-related positivity in primary and metastatic malignant melanoma. J Pathol 1994;172(4):343-8. http://dx.doi.org/ 10.1002/path.1711720409 (Pubitemid 24168651)
34. Ravindranath MH, Shen P, Habal N, Soh D, Nishimoto K, Gonzales A, Tarn WY, Bilchik A, Morton DL. Does human melanoma express carcinoembryonic antigen? Anticancer Res 2000;20(5 A):3083-92.
35. Selby WL, Nance KV, Park HK. CEA immunoreactivity in metastatic malignant melanoma. Mod Pathol 1992;5(4):415-9.
36. Kim CJ, Reintgen DS, Balch CM; AJCC Melanoma Staging Committee. The newmelanoma staging system. Cancer Control 2002;9(1):9-15.
37. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A Jr, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-48. (Pubitemid 32786276)
38. Blaheta HJ, Schittek B, Breuninger H, Garbe C. Detection of micrometastasis in sentinel lymph nodes of patients with primary cutaneous melanoma. Recent Results Cancer Res 2001;158:137-46. http://dx.doi.org/10.1007/ 978-3-642-59537-0-14
39. Karimipour DJ, Lowe L, Su L, Hamilton T, Sondak V, Johnson TM, Fullen D. Standard immunostains for melanoma in sentinel lymph node specimens: which ones are most useful? J Am Acad Dermatol 2004;50(5):759-64. http://dx.doi.org/10. 1016/j.jaad.2003.07.016 (Pubitemid 38580556)
40. Kucher C, Zhang PJ, Acs G, Roberts S, Xu X. Can Melan-A replace S-100 and HMB-45 in the evaluation of sentinel lymph nodes from patients with malignant melanoma?. Appl Immunohistochem Mol Morphol 2006;14(3):324-7. http://dx.doi.org/10.1097/00129039-200609000-00011 (Pubitemid 44319059)
41. Okegawa T, Pong RC, Li Y, Hsieh JT. The role of cell adhesion molecule in cancer progression and its application in cancer therapy. Acta Biochim Pol 2004;51:445-57. (Pubitemid 38969306)
42. Brooks SA. The involvement of Helix pomatia lectin (HPA) binding N-acetylgalactosamine glycans in cancer progression. Histol Histopathol 2000;15(1):143-58. (Pubitemid 30044299)
43. Pryme IF, Bardocz S, Pusztai A, Ewen SW. Suppression of growth of tumour cell lines in vitro and tumours in vivo by mistletoe lectins. Histol Histopathol 2006;21(3):285-99. (Pubitemid 43033738)
44. Szasz F, Sirivaidyapong S, Cheng FP, Voorhout WF, Marks A, Colenbrander B, Solti And L, Gadella BM. Detection of calcium ionophore induced membrane changes in dog sperm as a simple method to predict the cryopreservability of dog semen. Mol Reprod Dev 2000;55(3):289-98. http://dx.doi.org/10.1002/(SICI)1098- 2795(200003)55:3<289::AID-MRD7>3.0.CO;2-K (Pubitemid 30082890)
45. Avilés M, Castells MT, Martínez-Menárguez JA, Abascal I, Ballesta J. Localization of penultimate carbohydrate residues in zona pellucida and acrosomes by means of lectin cytochemistry and enzymatic treatments. Histochem J 1997;29(8):583-92. (Pubitemid 27431487)
46. Chen L, Ko CP. Extension of synaptic extracellular matrix during nerve terminal sprouting in living frog neuromuscular junctions. J Neurosci 1994;14(2):796-808. (Pubitemid 24043932)
47. Cochran AJ, Wen DR, Berthier-Vergnes O, Bailly C, Dore JF, Berard F, Moulin G, Thomas L. Cytoplasmic accumulation of peanut agglutinin-binding glycoconjugates in the cells of primary melanoma correlates with clinical outcome. Hum Pathol 1999;30(5):556-61. http://dx.doi.org/10.1016/S0046-8177 (99) 90201-0 (Pubitemid 29218050)
48. Ota T, Kohno H, Maeda M, Tanino M, Odashima S. Involvement of peanut agglutinin-binding sugar chains in experimental metastasis of B16 melanoma cells. Oncol Res 1993;5(6-7):235-43. (Pubitemid 24019008)
49. Carmeliet P. Manipulating angiogenesis in medicine. J Intern Med 2004;255:538-61. http://dx.doi.org/10.1111/j.1365-2796.2003.01297.x (Pubitemid 38534868)
50. Folkman J. Fundamental concepts of the angiogenic process. Curr Mol Med 2003;3:643-51. http://dx.doi.org/10.2174/1566524033479465 (Pubitemid 37236406)
51. Dejana E, Spagnuolo R, Bazzoni G. Interendothelial junctions and their role in the control of angiogenesis, vascular permeability and leukocyte transmigration. Thromb Haemost 2001;86:308-15. (Pubitemid 32663961)
52. Ergun S, Kilik N, Ziegeler G, Hansen A, Nollau P, Gotze J, Wurmbach J H, Horst A, Weil J, Fernando M, Wagener C. CEA-related cell adhesion molecule 1: a potent angiogenic factor and a major effector of vascular endothelial growth factor. Mol Cell 2000;5:311-20. http://dx.doi.org/10.1016/S1097-2765 (00) 80426-8 (Pubitemid 30628089)
53. Kilic N, Oliveira-Ferrer L, Wurmbach JH, Loges S, Chalajour F, Neshat-Vahid S, Weil J, Fernando M, Ergun S. Pro-angiogenic signaling by the endothelial presence of CEACAM1. J Biol Chem 2005;280:2361-9. http://dx.doi.org/10.1074/jbc. M409407200
54. Oliveira-Ferrer L, Tilki D, Ziegeler G, Hauschild J, Loges S, Irmak S, Kilic E, Huland H, Friedrich M, Ergun S. Dual role of carcinoembryonic antigen-related cell adhesion molecule 1 in angiogenesis and invasion of human urinary bladder cancer. Cancer Res 2004;64:8932-8. http://dx.doi.org/10.1158/ 0008-5472. CAN-04-0505 (Pubitemid 39665500)
55. Tilki D, Irmak S, Oliveira-Ferrer L, Hauschild J, Miethe K, Atakaya H, Hammerer P, Friedrich MG, Schuch G, Galalae R, Stief CG, Kilic E, Huland H, Ergun S. CEA-related cell adhesion molecule-1 is involved in angiogenic switch in prostate cancer. Oncogene 2006;25:4965-74. http://dx.doi.org/10.1038/sj.onc. 1209514
56. Dango S, Sienel W, Schreiber M, Stremmel C, Kirschbaum A, Pantel K, Passlick B. Elevated expression of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM-1) is associated with increased angiogenic potential in nonsmall-cell lung cancer. Lung Cancer 2008;60(3):426-33. http://dx.doi.org/10.1016/j.lungcan. 2007.11.015
57. Liu W, Wei W, Winer D, Bamberger A-M, Bamberger C, Wagener C, Ezzat S, Asa SL. CEACAM1 impedes thyroid cancer growth but promotes invasiveness: a putative mechanism for early metastases. Oncogene 2007;26:2747-58. http://dx.doi.org/10.1038/sj.onc.1210077 (Pubitemid 46663832)
58. Dupont WD, Pari FF, Hartmann WH, Brinton LA, Winfield AC, Worrell JA, Schuyler PA, Plummer WD. Breast cancer risk associated with proliferative breast disease and atypicalhyperplasia. Cancer 1993;71:1258-65. http://dx.doi.org/10. 1002/1097-0142 (19930215) 71:4<1258:: AID-CNCR2820710415>3.0. CO;2-I (Pubitemid 23054916)
59. Ouyang XS, Wang X, Ling MT, Wong HL, Tsao SW, Wong YC. Id-1 stimulates serum independent prostate cancer cell proliferation through inactivation of p16 (INK4a)/pRB pathway. Carcinogenesis 2002;23:721-5. http://dx.doi.org/10.1093/ carcin/23.5.721 (Pubitemid 34567509)
60. Singh J, Murata K, Itahana Y, Desprez PY. Constitutive expression of the Id-1 promoter in human metastatic breast cancer cells is linked with the loss of NF-1/Rb/HDAC-1 transcription repressor complex. Oncogene 2002;21(12):1812-22. http://dx.doi.org/10.1038/sj.onc.1205252 (Pubitemid 34259183)
61. Schoppmann SF, Schindl M, Bayer G, Aumayr K, Dienes J, Horvat R, Rudas M, Gnant M, Jakesz R, Birner P. Overexpression of Id-1 is associated with poor clinical outcome in node negative breast cancer. Int J Cancer 2003;104:677-82. http://dx.doi.org/10.1002/ijc.11009 (Pubitemid 36418503)
62. Liu Q, Yang YM, Zhang QH, Zhang TG, Zhou Q, Zhou CJ. Inhibitor of differentiation is overexpressed with progression of benign to malignantlesions and related with CEACAM1 distribution in mammary glands. Ann Diagn Pathol 2011;15(1):30-6. http://dx.doi.org/10.1016/j.anndiagpath.2010.07.010
63. Zhou CJ, Liu B, Zhu KX, Zhang QH, Zhang TG, Xu WH, Wang HB, Yu WH, Qu YD, Wang HJ, Wu HL, Sun SZ, Guo JQ. The different expression of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) and possible roles in gastric carcinomas. Pathol Res Pract 2009;205(7):483-9. http://dx.doi.org/10.1016/j. prp. 2009.01.006
64. Cavallaro U, Christofori G. Cell adhesion in tumor invasion and metastasis: loss of the glue is not enough. Biochim Biophys Acta 2001;1552:39-45. http://dx.doi.org/10.1016/S0304-419X (01) 00038-5 (Pubitemid 34066627)
65. Pignatelli M, Vessey C J. Adhesion molecules: novel molecular tools in tumor pathology. Hum Pathol 1994;25:849-56. http://dx.doi.org/10.1016/0046-8177 (94) 90002-7 (Pubitemid 24292399)
66. Brummer J, Ebrahimnejad A, Flayeh R, Schumacher U, Loning T, Bamberger AM, Wagener C. Cis Interaction of the cell adhesion molecule CEACAM1 with integrin beta (3) Am J Pathol 2001;159(2):537-46 http://dx.doi.org/10.1016/ S0002-9440 (10) 61725-7 (Pubitemid 32751084)
67. Howe HL, Wingo PA, Thun MJ, Ries LA, Rosenberg HM, Feigal EG, Edwards BK. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 2001;93:824-42. http://dx.doi.org/10.1093/jnci/93.11.824 (Pubitemid 32586611)
68. Torky M, el Zeky F, Hall JC. Significant changes in the distribution of histologic types of lung cancer. A review of 4928 cases. Cancer 1990;65:2361-7. http://dx.doi.org/10.1002/1097-0142 (19900515) 65:10<2361:: AID-CNCR2820651034>3.0. CO;2-C (Pubitemid 20164850)
69. Sienel W, Dango S, Woelfle U, Morresi-Hauf A, Wagener C, Brümmer J, Mutschler W, Passlick B, Pantel K. Elevated expression of carcinoembryonic antigen-related cell adhesion molecule 1 promotes progression of non-small cell lung cancer. Clin Cancer Res 2003;9(6):2260-6. (Pubitemid 36687651)
70. Liu NS, Spitz MR, Kemp BL, Cooksley C, Fossella FV, Lee JS, Hong WK, Khuri FR. Adenocarcinoma of the lung in young patients: The M. D. Anderson experience. Cancer 2000;88:1837-41. http://dx.doi.org/10.1002/(SICI) 1097-0142 (20000415) 88:8<1837::AID-CNCR12>3.0. CO;2-E (Pubitemid 30212993)
71. Thörn I, Schult-Kronefeld O, Burkholder I, Schuch G, Andritzky B, Kastendieck H, Edler L, Wagener C, Bokemeyer C, Schumacher U, Laack E. Expression of CEACAM-1 in pulmonary adenocarcinomas and their metastases. Anticancer Res 2009;9(1):249-54.
72. Ieda J, Yokoyama S, Tamura K, Takifuji K, Hotta T, Matsuda K, Oku Y, Nasu T, Kiriyama S, Yamamoto N, Nakamura Y, Shively JE, Yamaue H. Re-expression of CEACAM1 long cytoplasmic domain isoform is associated with invasion and migration of colorectal cancer. Int J Cancer 2011;129(6):1351-61. http://dx.doi.org/10.1002/ijc.26072
73. Scagliotti GV, Novello S, Selvaggi G. Multidrug resistance in non-small-lung cancer. Ann Oncol 1999;10(Suppl. 5):S83-6. http://dx.doi.org/10. 1093/annonc/10.suppl-5. S83
74. Gottesman MM, Fojo T, Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58. http://dx.doi.org/10. 1038/nrc706 (Pubitemid 37328807)